On this page you will find the key publications on COVID-19 and psoriasis selected by IPC's Chief Medical Officer.
may 2020 Teledermatologic monitoring for chronic cutaneous autoimmune diseases with smartworking during Covid-19 emergency in a tertiary center in Italy. [published online ahead of print, 2020 May 26]. Brunasso AMG, Massone C. 2020;e13495. doi:10.1111/dth.13695. Chilblain-like lesions: a case series of 41 patients during the COVID-19 pandemic. López-Robles J, de la Hera I, Pardo J, Martínez J, Cutillas-Marco E. Clin Exp Dermatol. 2020 May 5. doi: 10.1111/ced.14275. [Epub ahead of print] Performing dermoscopy in the COVID-19 pandemic. Goldust M, Zalaudek I, Gupta A, Lallas A, Rudnicka L, Navarini AA. Dermatol Ther. 2020 May 5:e13506. doi: 10.1111/dth.13506. [Epub ahead of print] Inpatient Teledermatology During the COVID-19 Pandemic. Rismiller K, Cartron AM, Trinidad JCL. J Dermatolog Treat. 2020 May 4:1-9. doi: 10.1080/09546634.2020.1762843. [Epub ahead of print] Leveraging Technology for Remote Learning in the Era of COVID-19 and Social Distancing: Tips and Resources for Pathology Educators and Trainees. Mukhopadhyay S, Booth AL, Calkins SM, Doxtader EE, Fine SW, Gardner JM, Gonzalez RS, Mirza KM, Jiang XS. Arch Pathol Lab Med. 2020 May 4. doi: 10.5858/arpa.2020-0201-ED. [Epub ahead of print] The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A metaestimate of pivotal trials relevant to decision-making during the COVID-19 pandemic. Wan MT, Shin DB, Winthrop KL, Gelfand JM. Journal of the American Academy of Dermatology. 2020. doi: https://doi.org/10.1016/j.jaad.2020.05.035. Practice guidelines for teledermatology in Australia. Abbott LM, Miller R, Janda M, Bennett H, Taylor M, Arnold C, Shumack S, Soyer HP, Caffery LJ. Australas. J Dermatol. 2020 May 3. doi: 10.1111/ajd.13301. [Epub ahead of print] The Virologic and Immunologic Effects of Cyclosporine as an Adjunct to Antiretroviral Therapy in Patients Treated during Acute and Early HIV-1 Infection. Martin Markowitz, Florin Vaida, C. Bradley Hare, Daniel Boden, Hiroshi Mohri, Frederick M. Hecht, Robert C. Kalayjian, Ann Conrad, Donna Mildvan, Judith Aberg, Christine Hogan, J. Michael Kilby, Henry H. Balfour, Jr, Kim Schafer, Douglas Richman, Susan Little. The Journal of Infectious Diseases, Volume 201, Issue 9, 1 May 2010, Pages 1298–1302, https://doi.org/10.1086/651664 april 2020 Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York. A. Chen, R. Castillo, S. Adhikari, D. Hudesma. Letter to the editor.NEJM. April 29, 2020. DOI: 10.1056/NEJMc2009567 Classification of the cutaneous manifestations of COVID‐19: a rapid prospective nationwide consensus study in Spain with 375 cases. C. Galván Casas A. Català G. Carretero Hernández P. Rodríguez‐Jiménez D. Fernández Nieto A. Rodríguez‐Villa Lario I. Navarro Fernández R. Ruiz‐Villaverde D. Falkenhain M. Llamas Velasco J. García‐Gavín O. Baniandrés C. González‐Cruz V. Morillas‐Lahuerta X. Cubiró I. Figueras Nart G. Selda‐Enriquez J. Romaní X. Fustà‐Novell A. Melian‐Olivera M. Roncero Riesco P. Burgos‐Blasco J. Sola Ortigosa M. Feito Rodriguez I. García‐Dova. First published:29 April 2020 BJD Dermatologists and SARS-CoV-2: The impact of the pandemic on daily practice. Gisondi P, Piaserico S, Conti A, Naldi L. J Eur Acad Dermatol Venereol.2020 Apr 22. doi: 10.1111/jdv.16515. [Epub ahead of print] Review. Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment. Gisondi P, Zaza G, Del Giglio M, Rossi M, Iacono V, Girolomoni G, R. Journal of the American Academy of Dermatology (2020), DOI: https://doi.org/10.1016/ j.jaad.2020.04.085. Dermatologists and SARS-CoV-2: The impact of the pandemic on daily practice. Gisondi P, Piaserico S, Conti A, Naldi L. J Eur Acad Dermatol Venereol. 2020 Apr 22. doi: 10.1111/jdv.16515. [Epub ahead of print] Review. Successful Guselkumab treatment in a psoriatic patient affected with Cornelia de Lange Syndrome, and prosecution during the COVID-19 pandemic. Mugheddu C, Dell'Antonia M, Sanna S, Agosta D, Atzori L, Rongioletti F. Dermatol Ther. 2020 Apr 18. doi: 10.1111/dth.13433. [Epub ahead of print] Successful Guselkumab treatment in a psoriatic patient affected with Cornelia de Lange Syndrome, and prosecution during the COVID-19 pandemic. Mugheddu C, Dell'Antonia M, Sanna S, Agosta D, Atzori L, Rongioletti F. Dermatol Ther. 2020 Apr 18. doi: 10.1111/dth.13433. [Epub ahead of print] COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Schett, G., Sticherling, M. & Neurath, M.F. COVID-19: risk for cytokine targeting in chronic inflammatory diseases?. Nat Rev Immunol (2020). https://doi.org/10.1038/s41577-020-0312-7 Journal articles on coronavirus with relevance for skin diseases and dermatology | Centre of Evidence Based Dermatology (CEBD) Coronavirus Resource for Dermatology https://www.nottingham.ac.uk/research/groups/cebd/resources/coronavirus-resource/journal-articles.aspx [visited April 20, 2020] march 2020 Cutaneous manifestations in COVID‐19: a first perspective. S. Recalcati. JEADV (26 March 2020) https://doi.org/10.1111/jdv.16387 Skin manifestations are emerging in the coronavirus pandemic. M. Alexander Otto. Article from website visited April 3, 2020 COVID-19: combining antiviral and anti-inflammatory treatments. Stebbing J, Phelan A, Griffin I, Tucker C, Oechsie O, Smith D, Richardson P. Lancet Infect Dis. 2020 Apr;20(4):400-402. doi: 10.1016/S1473-3099(20)30132-8. Epub 2020 Feb 27. Baricitinib for COVID-19: a suitable treatment? Favalli EG, Biggioggero M, Maioli G, Caporali R. Lancet Infect Dis. 2020 Apr 3. pii: S1473-3099(20)30262-0. doi: 10.1016/S1473-3099(20)30262-0. [Epub ahead of print] Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. [published online ahead of print, 2020 Apr 22]. J Infect. 2020;S0163-4453(20)30228-0. doi:10.1016/j.jinf.2020.04.017 Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic. Torres T, Puig L. Am J Clin Dermatol. 2020 Apr 10. doi: 10.1007/s40257-020-00514-2. [Epub ahead of print] One more paper towel, longer protection. Yu N, Wu L, Su J, Huang K, Zhao S, Chen X. J Am Acad Dermatol. 2020 Apr 1. pii: S0190-9622(20)30486-2. doi: 10.1016/j.jaad.2020.03.064. [Epub ahead of print] COVID-19 and Immunomodulator / Immunosuppressant Use in Dermatology. Price KN, Frew JW, Hsiao JL, Shi VY. J Am Acad Dermatol. 2020 May;82(5):e173-e175. doi: 10.1016/j.jaad.2020.03.046. Epub 2020 Mar 26. february 2020 Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Richardson P, Griffin I, Tucker C, Smith D, Oechsie O, Phelan A, Stebbing J Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4.
may 2020
Teledermatologic monitoring for chronic cutaneous autoimmune diseases with smartworking during Covid-19 emergency in a tertiary center in Italy. [published online ahead of print, 2020 May 26]. Brunasso AMG, Massone C. 2020;e13495. doi:10.1111/dth.13695.
Chilblain-like lesions: a case series of 41 patients during the COVID-19 pandemic. López-Robles J, de la Hera I, Pardo J, Martínez J, Cutillas-Marco E. Clin Exp Dermatol. 2020 May 5. doi: 10.1111/ced.14275. [Epub ahead of print]
Performing dermoscopy in the COVID-19 pandemic. Goldust M, Zalaudek I, Gupta A, Lallas A, Rudnicka L, Navarini AA. Dermatol Ther. 2020 May 5:e13506. doi: 10.1111/dth.13506. [Epub ahead of print] Inpatient Teledermatology During the COVID-19 Pandemic. Rismiller K, Cartron AM, Trinidad JCL. J Dermatolog Treat. 2020 May 4:1-9. doi: 10.1080/09546634.2020.1762843. [Epub ahead of print] Leveraging Technology for Remote Learning in the Era of COVID-19 and Social Distancing: Tips and Resources for Pathology Educators and Trainees. Mukhopadhyay S, Booth AL, Calkins SM, Doxtader EE, Fine SW, Gardner JM, Gonzalez RS, Mirza KM, Jiang XS. Arch Pathol Lab Med. 2020 May 4. doi: 10.5858/arpa.2020-0201-ED. [Epub ahead of print]
The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A metaestimate of pivotal trials relevant to decision-making during the COVID-19 pandemic. Wan MT, Shin DB, Winthrop KL, Gelfand JM. Journal of the American Academy of Dermatology. 2020. doi: https://doi.org/10.1016/j.jaad.2020.05.035.
Practice guidelines for teledermatology in Australia. Abbott LM, Miller R, Janda M, Bennett H, Taylor M, Arnold C, Shumack S, Soyer HP, Caffery LJ. Australas. J Dermatol. 2020 May 3. doi: 10.1111/ajd.13301. [Epub ahead of print]
The Virologic and Immunologic Effects of Cyclosporine as an Adjunct to Antiretroviral Therapy in Patients Treated during Acute and Early HIV-1 Infection. Martin Markowitz, Florin Vaida, C. Bradley Hare, Daniel Boden, Hiroshi Mohri, Frederick M. Hecht, Robert C. Kalayjian, Ann Conrad, Donna Mildvan, Judith Aberg, Christine Hogan, J. Michael Kilby, Henry H. Balfour, Jr, Kim Schafer, Douglas Richman, Susan Little. The Journal of Infectious Diseases, Volume 201, Issue 9, 1 May 2010, Pages 1298–1302, https://doi.org/10.1086/651664
april 2020 Covid-19 in Immune-Mediated Inflammatory Diseases — Case Series from New York. A. Chen, R. Castillo, S. Adhikari, D. Hudesma. Letter to the editor.NEJM. April 29, 2020. DOI: 10.1056/NEJMc2009567
Classification of the cutaneous manifestations of COVID‐19: a rapid prospective nationwide consensus study in Spain with 375 cases. C. Galván Casas A. Català G. Carretero Hernández P. Rodríguez‐Jiménez D. Fernández Nieto A. Rodríguez‐Villa Lario I. Navarro Fernández R. Ruiz‐Villaverde D. Falkenhain M. Llamas Velasco J. García‐Gavín O. Baniandrés C. González‐Cruz V. Morillas‐Lahuerta X. Cubiró I. Figueras Nart G. Selda‐Enriquez J. Romaní X. Fustà‐Novell A. Melian‐Olivera M. Roncero Riesco P. Burgos‐Blasco J. Sola Ortigosa M. Feito Rodriguez I. García‐Dova. First published:29 April 2020 BJD
Dermatologists and SARS-CoV-2: The impact of the pandemic on daily practice. Gisondi P, Piaserico S, Conti A, Naldi L. J Eur Acad Dermatol Venereol.2020 Apr 22. doi: 10.1111/jdv.16515. [Epub ahead of print] Review.
Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biological treatment and renal transplanted recipients in maintenance immunosuppressive treatment. Gisondi P, Zaza G, Del Giglio M, Rossi M, Iacono V, Girolomoni G, R. Journal of the American Academy of Dermatology (2020), DOI: https://doi.org/10.1016/ j.jaad.2020.04.085.
Dermatologists and SARS-CoV-2: The impact of the pandemic on daily practice. Gisondi P, Piaserico S, Conti A, Naldi L. J Eur Acad Dermatol Venereol. 2020 Apr 22. doi: 10.1111/jdv.16515. [Epub ahead of print] Review.
Successful Guselkumab treatment in a psoriatic patient affected with Cornelia de Lange Syndrome, and prosecution during the COVID-19 pandemic. Mugheddu C, Dell'Antonia M, Sanna S, Agosta D, Atzori L, Rongioletti F. Dermatol Ther. 2020 Apr 18. doi: 10.1111/dth.13433. [Epub ahead of print] Successful Guselkumab treatment in a psoriatic patient affected with Cornelia de Lange Syndrome, and prosecution during the COVID-19 pandemic. Mugheddu C, Dell'Antonia M, Sanna S, Agosta D, Atzori L, Rongioletti F. Dermatol Ther. 2020 Apr 18. doi: 10.1111/dth.13433. [Epub ahead of print]
COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Schett, G., Sticherling, M. & Neurath, M.F. COVID-19: risk for cytokine targeting in chronic inflammatory diseases?. Nat Rev Immunol (2020). https://doi.org/10.1038/s41577-020-0312-7
Journal articles on coronavirus with relevance for skin diseases and dermatology | Centre of Evidence Based Dermatology (CEBD) Coronavirus Resource for Dermatology https://www.nottingham.ac.uk/research/groups/cebd/resources/coronavirus-resource/journal-articles.aspx [visited April 20, 2020]
march 2020
Skin manifestations are emerging in the coronavirus pandemic. M. Alexander Otto. Article from website visited April 3, 2020
One more paper towel, longer protection. Yu N, Wu L, Su J, Huang K, Zhao S, Chen X. J Am Acad Dermatol. 2020 Apr 1. pii: S0190-9622(20)30486-2. doi: 10.1016/j.jaad.2020.03.064. [Epub ahead of print]
COVID-19 and Immunomodulator / Immunosuppressant Use in Dermatology. Price KN, Frew JW, Hsiao JL, Shi VY. J Am Acad Dermatol. 2020 May;82(5):e173-e175. doi: 10.1016/j.jaad.2020.03.046. Epub 2020 Mar 26.
february 2020
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Richardson P, Griffin I, Tucker C, Smith D, Oechsie O, Phelan A, Stebbing J Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4.
Return to resource center
EXPert opinions Commentaries on select publications learn more
recent publications on COVID-19 & PSORIASIS Severe COVID-19 outcomes in patients with psoriasis. Severe COVID-19 outcomes in patients with psoriasis. J Eur Acad Dermatol Venereol. 2020 Aug 11;: Authors: Lima XT, Cueva MA, Lopes EM, Alora MB Abstract Psoriasis is a chronic inflammatory disease associated with comorbidities known to increase risk of severe COVID-19, such as hypertension, cardiovascular disease, diabetes and obesity.1,2 Use of systemic therapies may increase a patient's risk of infections.3 Our study aims to evaluate the association of psoriasis systemic therapy and COVID outcomes. PMID: 32780905 [PubMed - as supplied by publisher] Concerns related to the COVID-19 pandemic in adult patients with atopic dermatitis and psoriasis treated with systemic immunomodulatory therapy: a Danish questionnaire survey.Related Articles Concerns related to the COVID-19 pandemic in adult patients with atopic dermatitis and psoriasis treated with systemic immunomodulatory therapy: a Danish questionnaire survey. J Eur Acad Dermatol Venereol. 2020 Aug 11;: Authors: Dyrberg Loft N, Halling AS, Iversen L, Vestergaard C, Deleuran M, Rasmussen MK, Zachariae C, Thyssen JP, Skov L Abstract Patients with moderate-to-severe atopic dermatitis (AD) or psoriasis often require systemic immunomodulatory therapy. The uncertainty of the potential of these therapies to increase the risk of more serious illness due to Coronavirus disease 2019 (COVID-19) may have caused anxiety and led to treatment discontinuation. Therefore, we conducted an anonymous questionnaire on concerns of COVID-19 in patients with AD or psoriasis treated with systemic immunomodulatory therapy. PMID: 32780487 [PubMed - as supplied by publisher] View all publications from PubMed
recent publications on COVID-19 & PSORIASIS
Severe COVID-19 outcomes in patients with psoriasis.
J Eur Acad Dermatol Venereol. 2020 Aug 11;:
Authors: Lima XT, Cueva MA, Lopes EM, Alora MB
Abstract Psoriasis is a chronic inflammatory disease associated with comorbidities known to increase risk of severe COVID-19, such as hypertension, cardiovascular disease, diabetes and obesity.1,2 Use of systemic therapies may increase a patient's risk of infections.3 Our study aims to evaluate the association of psoriasis systemic therapy and COVID outcomes.
PMID: 32780905 [PubMed - as supplied by publisher]
Concerns related to the COVID-19 pandemic in adult patients with atopic dermatitis and psoriasis treated with systemic immunomodulatory therapy: a Danish questionnaire survey.
Authors: Dyrberg Loft N, Halling AS, Iversen L, Vestergaard C, Deleuran M, Rasmussen MK, Zachariae C, Thyssen JP, Skov L
Abstract Patients with moderate-to-severe atopic dermatitis (AD) or psoriasis often require systemic immunomodulatory therapy. The uncertainty of the potential of these therapies to increase the risk of more serious illness due to Coronavirus disease 2019 (COVID-19) may have caused anxiety and led to treatment discontinuation. Therefore, we conducted an anonymous questionnaire on concerns of COVID-19 in patients with AD or psoriasis treated with systemic immunomodulatory therapy.
PMID: 32780487 [PubMed - as supplied by publisher]
View all publications from PubMed